トップページ　>　ドージンニュース　>　Vol.178　>　Review 2 ：Ferroptosis: Beauty or the Beast

Ferroptosis: Beauty or the Beast

［References］

1） B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, A. I. Bush, M. Conrad, S. J. Dixon, S. Fulda, S. Gascon, S. K. Hatzios, V. E. Kagan, K. Noel, X. Jiang, A. Linkermann, M. E. Murphy, M. Overholtzer, A. Oyagi, G. C. Pagnussat, J. Park, Q. Ran, C. S. Rosenfeld, K. Salnikow, D. Tang, F. M. Torti, S. V. Torti, S. Toyokuni, K. A. Woerpel and D. D. Zhang, “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease”, Cell, 2017, 171(2), 273-285.
2） X. Jiang, B. R. Stockwell and M. Conrad, “Ferroptosis: mechanisms, biology and role in disease”, Nat. Rev. Mol. Cell Biol., 2021, 22(4), 266-282.
3） Y. Yu, L. Jiang, H. Wang, Z. Shen, Q. Cheng, P. Zhang, J. Wang, Q. Wu, X. Fang, L. Duan, S. Wang, K. Wang, P. An, T. Shao, R. T. Chung, S. Zheng, J. Min and F. Wang, “Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis”, Blood, 2020, 136(6), 726-739.
4） X. Fang, H. Wang, D. Han, E. Xie, X. Yang, J. Wei, S. Gu, F. Gao, N. Zhu, X. Yin, Q. Cheng, P. Zhang, W. Dai, J. Chen, F. Yang, H. T. Yang, A. Linkermann, W. Gu, J. Min and F. Wang, “Ferroptosis as a target for protection against cardiomyopathy”, Proc. Natl. Acad. Sci. U S A, 2019, 116(7), 2672-2680.
5） J. Zheng and M. Conrad, “The metabolic Underpinnings of Ferroptosis”, Cell Metab., 2020, 32(6), 920-937.
6） B. Chu, N. Kon, D. Chen, T. Li, T. Liu, L. Jiang, S. Song, O. Tavana and W. Gu, “ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway”, Nat. Cell Biol., 2019, 21(5), 579-591.
7） C. Mao, X. Liu, Y. Zhang, G. Lei, Y. Yan, H. Lee, P. Koppula, S. Wu, L. Zhuang, B. Fang, M. V. Poyurovsky, K. Olszewski and B. Gan, “DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer”, Nature, 2021, 593, 586-590. DOI: 10.1038/s41586-021-03539-7
8） S. J. Dixon, D. N. Patel, M. Welsch, R. Skouta, E. D. Lee, M. Hayano, A. G. Thomas, C. E. Gleason, N. P. Tatonetti, B. S. Slusher and B. R. Stockwell, “Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis”, Elife, 2014, 3, e02523.
9） L. Jiang, J. Wang, K. Wang, H. Wang, Q. Wu, C. Yang, Y. Yu, P. Ni, Y. Zhong, Z. Song, E. Xie, R. Hu, J. Min and F. Wang, “RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation”, Blood, 2021, DOI: 10.1182/blood.2020008986
10） H. Wang, C. Liu, Y. Zhao and G. Gao, “Mitochondria regulation in ferroptosis”, Eur. J. Cell Biol., 2020, 99(1), 151058.
11） Y. S. Lee, D. H. Lee, H. A. Choudry, D. L. Bartlett and Y. J. Lee, “Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis”, Mol. Cancer Res., 2018, 16(7), 1073-1076.
12） Y. Wu, S. Zhang, X. Gong, S. Tam, D. Xiao, S. Liu and Y. Tao, “The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression”, Mol. Cancer, 2020, 19(1), 39.
13） X. Chen, C. Yu, R. Kang and D. Tang, “Iron Metabolism in Ferroptosis”, Front. Cell Dev. Biol., 2020, 8: 590226.
14） T. M. Seibt, B. Proneth and M. Conrad, “Role of GPX4 in ferroptosis and its pharmacological implication”, Free Radic. Biol. Med., 2019, 133, 144-152.
15） J. R. Wu, Q. Z. Tuo and P. Lei, “Ferroptosis, a Recent Defined Form of Critical Cell Death in Neurological Disorders”, J. Mol. Neurosci., 2018, 66(2), 197-206.
16） Y. Xie, W. Hou, X. Song, Y. Yu, J. Huang, X. Sun, R. Kang and D. Tang, “Ferroptosis: process and function”, Cell Death Differ., 2016, 23(3), 369-379.
17） N. Kajarabille and G. O. Latunde-Dada “Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators”, Int. J. Mol. Sci., 2019, 20(19), 4968.
18） L. Devisscher, S. Van Coillie, S. Hofmans, D. Van Rompaey, K. Goossens, E. Meul, L. Maes, H. De Winter, P. Van Der Veken, P. Vandenabeele, T. V. Berghe and K. Augustyns, “Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy”, J. Med. Chem., 2018, 61(22), 10126-10140.
19） J. P. Friedmann Angeli, M. Schneider, B. Proneth, Y. Y. Tyurina, V. A. Tyurin, V. J. Hammond, N. Herbach, M. Aichler, A. Walch, E. Eggenhofer, D. Basavarajappa, O. Radmark, S. Kobayashi, T. Seibt, H. Beck, F. Neff, I. Esposito, R. Wanke, H. Forster, O. Yefremova, M. Heinrichmeyer, G. W. Bornkamm, E. K. Geissler, S. B. Thomas, B. R. Stockwell, V. B. O'Donnell, V. E. Kagan, J. A. Schick and M. Conrad, “Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice”, Nat. Cell Biol., 2014, 16(12), 1180-1191.
20） X. Fang, P. An, H. Wang, X. Wang, X. Shen, X. Li, J. Min, S. Liu and F. Wang, “Dietary intake of heme iron and risk of cardiovascular disease: A dose-response meta-analysis of prospective cohort studies”, Nutr. Metab. Cardiovasc. Dis., 2015, 25(1), 24-35.
21） X. Fang, Z. Cai, H. Wang, D. Han, Q. Cheng, P. Zhang, F. Gao, Y. Yu, Z. Song, Q. Wu, P. An, S. Huang, J. Pan, H. Z. Chen, J. Chen, A. Linkermann, J. Min and F. Wang, “Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis”, Circ. Res., 2020, 127(4), 486-501.
22） H. Wang, P. An, E. Xie, Q. Wu, X. Fang, H. Gao, Z. Zhang, Y. Li, X. Wang, J. Zhang, G. Li, L. Yang, W. Liu, J. Min and F. Wang, “Characterization of ferroptosis in murine models of hemochromatosis”, Hepatology, 2017, 66(2), 449-465.
23） R. Kang, G. Kroemer and D. Tang, “The tumor suppressor protein p53 and the ferroptosis network”, Free Radic. Biol. Med., 2019, 133, 162-168.
24） X. Chen, R. Kang, G. Kroemer and D. Tang, “Broadening horizons: the role of ferroptosis in cancer”, Nat. Rev. Clin. Oncol., 2021, 18(5), 280-296.
25） B. Hassannia, P. Vandenabeele and T. Vanden Berghe, “Targeting Ferroptosis to Iron Out Cancer”, Cancer Cell, 2019, 35(6), 830-849.
26） W. Wang, M. Green, J. E. Choi, M. Gijon, P. D. Kennedy, J. K. Johnson, P. Liao, X. Lang, I. Kryczek, A. Sell, H. Xia, J. Zhou, G. Li, J. Li, W. Li , S. Wei, L. Vatan, H. Zhang, W. Szeliga, W. Gu, R. Liu, T. S. Lawrence, C. Lamb, Y. Tanno, M. Cieslik, E. Stone, G. Georgiou, T. A. Chan, A. Chinnaiyan and W. Zou, “CD8^＋ T cells regulate tumour ferroptosis during cancer immunotherapy”, Nature, 2019, 569, 270-274.
27） C. O. Reichert, F. A. de Freitas, J. Sampaio-Silva, L. Rokita-Rosa, P. L. Barros, D. Levy and S. P. Bydlowski, “Ferroptosis Mechanisms Involved in Neurodegenerative Diseases”, Int. J. Mol. Sci., 2020, 21(22), 8765.